ES2979210T3 - Anticuerpos monoclonales anti-CTLA4 humano quiméricos y humanizados y usos de los mismos - Google Patents

Anticuerpos monoclonales anti-CTLA4 humano quiméricos y humanizados y usos de los mismos Download PDF

Info

Publication number
ES2979210T3
ES2979210T3 ES16876612T ES16876612T ES2979210T3 ES 2979210 T3 ES2979210 T3 ES 2979210T3 ES 16876612 T ES16876612 T ES 16876612T ES 16876612 T ES16876612 T ES 16876612T ES 2979210 T3 ES2979210 T3 ES 2979210T3
Authority
ES
Spain
Prior art keywords
ctla4
antibodies
antibody
mice
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES16876612T
Other languages
English (en)
Spanish (es)
Inventor
Yang Liu
Pan Zheng
Martin Devenport
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oncoc4 Inc
Original Assignee
Oncoc4 Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncoc4 Inc filed Critical Oncoc4 Inc
Application granted granted Critical
Publication of ES2979210T3 publication Critical patent/ES2979210T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
ES16876612T 2015-12-15 2016-12-14 Anticuerpos monoclonales anti-CTLA4 humano quiméricos y humanizados y usos de los mismos Active ES2979210T3 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562267735P 2015-12-15 2015-12-15
US201662309169P 2016-03-16 2016-03-16
US201662359036P 2016-07-06 2016-07-06
PCT/US2016/066698 WO2017106372A1 (en) 2015-12-15 2016-12-14 Chimeric and humanized anti-human ctla4 monoclonal antibodies and uses thereof

Publications (1)

Publication Number Publication Date
ES2979210T3 true ES2979210T3 (es) 2024-09-24

Family

ID=59057509

Family Applications (1)

Application Number Title Priority Date Filing Date
ES16876612T Active ES2979210T3 (es) 2015-12-15 2016-12-14 Anticuerpos monoclonales anti-CTLA4 humano quiméricos y humanizados y usos de los mismos

Country Status (26)

Country Link
US (3) US10618960B2 (enExample)
EP (2) EP3389699B1 (enExample)
JP (5) JP6858779B2 (enExample)
KR (2) KR20250108763A (enExample)
CN (2) CN108430499B (enExample)
AU (3) AU2016370648B2 (enExample)
BR (1) BR112018012113A2 (enExample)
CA (1) CA3006984C (enExample)
DK (1) DK3389699T5 (enExample)
ES (1) ES2979210T3 (enExample)
FI (1) FI3389699T3 (enExample)
HR (1) HRP20240719T1 (enExample)
HU (1) HUE066907T2 (enExample)
IL (3) IL296354B2 (enExample)
LT (1) LT3389699T (enExample)
MX (3) MX2018006925A (enExample)
MY (1) MY186974A (enExample)
PL (1) PL3389699T3 (enExample)
PT (1) PT3389699T (enExample)
RS (1) RS65703B1 (enExample)
SG (1) SG11201804969PA (enExample)
SI (1) SI3389699T1 (enExample)
SM (1) SMT202400211T1 (enExample)
TW (1) TWI739781B (enExample)
WO (1) WO2017106372A1 (enExample)
ZA (1) ZA201804077B (enExample)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3303394T1 (sl) 2015-05-29 2020-10-30 Agenus Inc. Protitelesa proti-CTLA-4 in postopki njihove uporabe
DK3515489T3 (da) 2016-09-19 2026-01-26 Oncoc4 Inc Cd80- og cd86-bindende proteinsammensætinger og deres anvendelse
US11013802B2 (en) 2016-12-07 2021-05-25 Agenus Inc. Anti-CTLA-4 antibodies and methods of use thereof
CN111511762B (zh) 2017-08-21 2025-05-06 天演药业公司 抗cd137分子及其用途
KR20200085828A (ko) * 2017-11-08 2020-07-15 젠코어 인코포레이티드 신규의 항-pd-1 서열을 사용한 이중특이적 및 단일특이적 항체
WO2019148444A1 (en) * 2018-02-02 2019-08-08 Adagene Inc. Anti-ctla4 antibodies and methods of making and using the same
CA3089704A1 (en) * 2018-02-02 2019-08-08 Oncoimmune, Inc. Methods of selecting and designing safer and more effective anti-ctla-4 antibodies for cancer therapy
CA3089768A1 (en) * 2018-02-02 2019-08-08 Oncoimmune, Inc. Mutant anti-ctla-4 antibodies with improved immunotherapeutic effect but attenuated adverse effects
WO2019148445A1 (en) 2018-02-02 2019-08-08 Adagene Inc. Precision/context-dependent activatable antibodies, and methods of making and using the same
EP3802613A4 (en) * 2018-06-05 2022-03-09 Jiangsu Alphamab Biopharmaceuticals Co., Ltd. DIMER AND ITS USE
EP3617230A1 (en) * 2018-09-03 2020-03-04 BioInvent International AB Novel antibodies and nucleotide sequences, and uses thereof
EP3898677A1 (en) 2018-12-21 2021-10-27 OSE Immunotherapeutics Bifunctional anti-pd-1/il-7 molecule
IL316757A (en) * 2018-12-27 2025-01-01 Gigagen Inc Anti-CTLA-4 binding proteins and methods of using them
WO2020165374A1 (en) 2019-02-14 2020-08-20 Ose Immunotherapeutics Bifunctional molecule comprising il-15ra
WO2021122866A1 (en) 2019-12-17 2021-06-24 Ose Immunotherapeutics Bifunctional molecules comprising an il-7 variant
CN115443291B (zh) * 2020-04-13 2025-08-05 博奥信生物技术（南京）有限公司 结合ctla4的抗体及其用途
AU2021262609A1 (en) 2020-05-01 2022-12-22 Kashiv Biosciences, Llc An improved process of purification of protein
WO2022112198A1 (en) 2020-11-24 2022-06-02 Worldwide Innovative Network Method to select the optimal immune checkpoint therapies
EP4255929A2 (en) 2020-12-02 2023-10-11 Vib Vzw An ltbr agonist in combination therapy against cancer
WO2022169269A1 (ko) * 2021-02-03 2022-08-11 주식회사 유틸렉스 항 ctla-4 항체 및 이의 용도
CA3213917A1 (en) 2021-04-09 2022-10-13 Nicolas Poirier New scaffold for bifunctional molecules with improved properties
WO2022214652A1 (en) 2021-04-09 2022-10-13 Ose Immunotherapeutics Scaffold for bifunctioanl molecules comprising pd-1 or cd28 and sirp binding domains
JP7345889B2 (ja) * 2021-06-17 2023-09-19 株式会社ニューギン 遊技機
US20250236640A1 (en) * 2021-10-08 2025-07-24 Kashiv Biosciences, Llc Separation of pre-peak in fusion protein sample by using size exclusion high performance liquid chromatography
WO2023057995A1 (en) * 2021-10-08 2023-04-13 Kashiv Biosciences, Llc Separation of pre-peak and post-peak in fusion protein sample by using size exclusion high performance liquid chromatography
EP4422685A4 (en) * 2021-10-29 2025-12-03 Oncoc4 Inc ANTI-CTLA-4 ANTIBODY DOSING SCHEMES
US20260035484A1 (en) * 2021-10-29 2026-02-05 Longbio Pharma (Suzhou) Co., Ltd. Isolated antigen binding protein and use thereof
WO2024003360A1 (en) 2022-07-01 2024-01-04 Institut Curie Biomarkers and uses thereof for the treatment of neuroblastoma
JP2025525886A (ja) 2022-08-02 2025-08-07 オーエスイー・イミュノセラピューティクス Ｃｄ２８に対する多機能性分子
JP2025531229A (ja) 2022-09-16 2025-09-19 オンコシーフォー、インク． 腺様嚢胞がんを処置するための抗ｃｔｌａ－４抗体の使用
WO2024194605A1 (en) 2023-03-17 2024-09-26 Quell Therapeutics Limited Treg therapy
WO2024200823A1 (en) 2023-03-30 2024-10-03 Ose Immunotherapeutics Lipid-based nanoparticle targeted at activated immune cells for the expression of immune cell enhancing molecule and use thereof
EP4687990A1 (en) 2023-03-30 2026-02-11 Ose Immunotherapeutics Method of synthesis of targeted lipid nanoparticle and uses thereof
EP4702051A1 (en) 2023-04-28 2026-03-04 OncoC4, Inc. Combinations of anti-ctla-4 antibodies and anti-pd-1 antibodies and therapeutic uses thereof
WO2024254403A2 (en) * 2023-06-09 2024-12-12 The Regents Of The University Of California Methods for identifying and correcting tumor humoral immune dysfunction
WO2025133186A1 (en) 2023-12-22 2025-06-26 OncoC4, Inc. Anti-ctla-4 antibody for treatment of patients with prostate cancer and combination therapy with a radioligand therapeutic agent
WO2025201659A1 (en) 2024-03-28 2025-10-02 BioNTech SE Combination therapy comprising therapeutic rna cancer vaccines and anti-ctla4 antibodies for cancer treatment
WO2025234450A1 (ja) * 2024-05-08 2025-11-13 学校法人帝京平成大学 改変がん細胞及びそれを含むがんワクチン組成物
WO2025242835A1 (en) 2024-05-22 2025-11-27 Ose Immunotherapeutics Molecules comprising masking linkers and uses thereof for the treatment of cancer
WO2026041780A2 (en) 2024-08-23 2026-02-26 BioNTech SE Combination therapy comprising anti-ctla4 antibodies and chemotherapy for cancer treatment

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
WO2001014557A1 (en) 1999-08-23 2001-03-01 Dana-Farber Cancer Institute, Inc. Pd-1, a receptor for b7-4, and uses therefor
CA2383424C (en) 1999-08-23 2011-02-15 Gordon Freeman Novel b7-4 molecules and uses therefor
US7605238B2 (en) * 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
EP3225632B1 (en) 1999-11-30 2020-05-06 Mayo Foundation for Medical Education and Research Antibodies binding to b7-h1, a novel immunoregulatory molecule
US6803192B1 (en) 1999-11-30 2004-10-12 Mayo Foundation For Medical Education And Research B7-H1, a novel immunoregulatory molecule
EP1261376A1 (en) * 2000-01-27 2002-12-04 Genetics Institute, LLC Antibodies against ctla4(cd152), conjugates comprising same, and uses thereof
AU2002258941A1 (en) 2001-04-20 2002-11-05 Mayo Foundation For Medical Education And Research Methods of enhancing cell responsiveness
CA2466279A1 (en) 2001-11-13 2003-05-22 Dana-Farber Cancer Institute, Inc. Agents that modulate immune cell activation and methods of use thereof
CN1753912B (zh) 2002-12-23 2011-11-02 惠氏公司 抗pd-1抗体及其用途
US20080152655A1 (en) * 2004-09-08 2008-06-26 The Ohio State University Research Foundation Combination Therapy With Anti-Ctla4 and Anti-4-1BB Antibodies
EP1793858A4 (en) * 2004-09-08 2008-12-10 Univ Ohio State Res Found HUMAN MONOCLONAL ANTI-CTLA4 ANTIBODIES FOR CANCER TREATMENT
KR20070050504A (ko) 2004-10-15 2007-05-15 베리사인 인코포레이티드 일회용 비밀번호
SG158919A1 (en) 2005-01-24 2010-02-26 Univ Texas Constructs binding to phosphatidylserine and their use in disease treatment
ES2720160T3 (es) * 2005-05-09 2019-07-18 Ono Pharmaceutical Co Anticuerpos monoclonales humanos contra muerte programada 1(PD-1) y métodos para tratar el cáncer usando anticuerpos dirigidos contra PD-1 solos o junto con otras sustancias inmunoterapéuticas
EA019344B1 (ru) 2005-07-01 2014-03-31 МЕДАРЕКС, Эл.Эл.Си. Человеческие моноклональные антитела против лиганда-1 запрограммированной гибели клеток (pd-l1) и их применения
US8062852B2 (en) 2007-10-01 2011-11-22 The Children's Hospital And Regional Medical Center Detection and treatment of autoimmune disorders
CN101628940B (zh) * 2008-07-15 2011-11-23 中国科学院生物物理研究所 一种单克隆抗体及其应用
GB0903325D0 (en) * 2009-02-26 2009-04-08 Univ Aberdeen Antibody molecules
GB201103955D0 (en) * 2011-03-09 2011-04-20 Antitope Ltd Antibodies
CN104114701A (zh) * 2011-12-22 2014-10-22 弗·哈夫曼-拉罗切有限公司 表达载体组织、新的生产用细胞产生方法及其在重组产生多肽中的用途
WO2013142796A2 (en) * 2012-03-23 2013-09-26 Bristol-Myers Squibb Company Methods of treatments using ctla4 antibodies
WO2014089113A1 (en) * 2012-12-03 2014-06-12 Bristol-Myers Squibb Company Enhancing anti-cancer activity of immunomodulatory fc fusion proteins
WO2014209804A1 (en) * 2013-06-24 2014-12-31 Biomed Valley Discoveries, Inc. Bispecific antibodies
CN104292334B (zh) * 2014-04-25 2018-11-27 河南省健康伟业生物医药研究股份有限公司 一种全人源抗ctla-4单克隆抗体、制备方法及应用
DK3515489T3 (da) 2016-09-19 2026-01-26 Oncoc4 Inc Cd80- og cd86-bindende proteinsammensætinger og deres anvendelse

Also Published As

Publication number Publication date
BR112018012113A2 (pt) 2018-12-04
HRP20240719T1 (hr) 2024-09-13
KR20250108763A (ko) 2025-07-15
HUE066907T2 (hu) 2024-09-28
JP7790837B2 (ja) 2025-12-23
JP2019510733A (ja) 2019-04-18
JP2025160458A (ja) 2025-10-22
DK3389699T5 (da) 2024-09-23
US12473362B2 (en) 2025-11-18
US20200283526A1 (en) 2020-09-10
DK3389699T3 (da) 2024-05-13
US10618960B2 (en) 2020-04-14
JP6858779B2 (ja) 2021-04-14
IL296354A (en) 2022-11-01
US20190127468A1 (en) 2019-05-02
EP3389699A4 (en) 2019-07-10
IL259988A (en) 2018-07-31
JP2022123049A (ja) 2022-08-23
JP7286845B2 (ja) 2023-06-05
NZ743013A (en) 2025-03-28
FI3389699T3 (fi) 2024-05-28
AU2026200849A1 (en) 2026-02-26
CA3006984C (en) 2023-10-17
CN116063492A (zh) 2023-05-05
EP4374926A3 (en) 2024-08-07
RS65703B1 (sr) 2024-07-31
US11629188B2 (en) 2023-04-18
EP4374926A2 (en) 2024-05-29
EP3389699A1 (en) 2018-10-24
PL3389699T3 (pl) 2024-07-22
SI3389699T1 (sl) 2024-07-31
IL259988B (en) 2022-10-01
JP2023106547A (ja) 2023-08-01
AU2023203169B2 (en) 2025-11-27
MX2018006925A (es) 2018-08-01
EP3389699B1 (en) 2024-05-01
MX2025001300A (es) 2025-03-07
KR102830926B1 (ko) 2025-07-08
MX2025001302A (es) 2025-03-07
PT3389699T (pt) 2024-06-04
AU2023203169A1 (en) 2023-06-15
TW201731877A (zh) 2017-09-16
LT3389699T (lt) 2024-06-10
JP2021100957A (ja) 2021-07-08
MY186974A (en) 2021-08-26
CN108430499A (zh) 2018-08-21
IL310404A (en) 2024-03-01
CN108430499B (zh) 2022-07-19
IL296354B1 (en) 2024-03-01
US20230391870A1 (en) 2023-12-07
IL296354B2 (en) 2024-07-01
KR20180086219A (ko) 2018-07-30
AU2016370648A1 (en) 2018-06-21
SG11201804969PA (en) 2018-07-30
AU2016370648B2 (en) 2023-03-09
ZA201804077B (en) 2019-09-25
IL259988B2 (en) 2023-02-01
TWI739781B (zh) 2021-09-21
CA3006984A1 (en) 2017-06-22
WO2017106372A1 (en) 2017-06-22
SMT202400211T1 (it) 2024-07-09

Similar Documents

Publication Publication Date Title
US12473362B2 (en) Chimeric and humanized anti-human CTLA4 monoclonal antibodies and uses thereof
TW202012434A (zh) 抗cd24組合物及其用途
TW202305005A (zh) 抗ｓｉｇｌｅｃ組合物及其用途
HK40110941A (en) Chimeric and humanized anti-human ctla4 monoclonal antibodies and uses thereof
KR20230009432A (ko) 활성화가능한 항-ctla-4 항체의 투약 및 투여
HK40092659A (zh) 嵌合和人源化抗人类ctla4单克隆抗体和其用途
EA038617B1 (ru) Химерные и гуманизированные античеловеческие ctla-4 моноклональные антитела и их использование
HK1259883A1 (en) Chimeric and humanized anti-human ctla4 monoclonal antibodies and uses thereof
HK1259883B (en) Chimeric and humanized anti-human ctla4 monoclonal antibodies and uses thereof
EA049996B1 (ru) Антитело к siglec-10 (варианты)